drugset

drugset / Trial / NCT00558493

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients

NCT00558493 ↗

Phase 4 Completed 100 enrolled Bukwang Pharmaceutical

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A multi-center and open study to compare the safety and effectiveness of switching treatment from lamivudine to clevudine for 24 weeks.

Timeline

Start: 2007-11
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clevudine	Small molecule	30 mg	—

Indications